{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T05:17:59Z","timestamp":1775798279683,"version":"3.50.1"},"reference-count":99,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tumor hypoxia is a critical contributor to cisplatin resistance, promoting molecular adaptations such as HIF-1\u03b1 activation, reduced DNA repair capacity, metabolic reprogramming, and exosome-mediated drug efflux that collectively weaken cisplatin-induced cytotoxicity. This review integrates current evidence on these hypoxia-driven mechanisms and emphasizes how spatially heterogeneous hypoxic niches generate tumor subpopulations with distinct resistance profiles. Two therapeutic strategies show promising potential to counter this challenge: adjunct therapies that target hypoxia-related signaling and metabolic pathways, including HIF inhibitors, HDAC inhibitors, natural compounds, and metabolic modulators, and oxygenation approaches designed to reverse hypoxic stress. Notably, advances in nanotechnology-based oxygen-delivery systems provide sustained, localized reoxygenation of hypoxic regions, addressing limitations of conventional oxygen therapies. Although these interventions demonstrate strong preclinical efficacy, translation to consistent clinical benefit remains limited, partly due to inadequate hypoxia biomarkers and insufficient preclinical models that fail to replicate tumor oxygen gradients. Future progress will require biomarker-guided patient selection, optimized combination regimens, and early clinical evaluation of oxygen-delivery platforms to enhance cisplatin sensitivity and reduce hypoxia-driven chemoresistance.<\/jats:p>","DOI":"10.1515\/jbcpp-2025-0092","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:56:43Z","timestamp":1773824203000},"page":"105-118","source":"Crossref","is-referenced-by-count":0,"title":["Hypoxia-induced cisplatin resistance in cancer: a comprehensive exploration of molecular mechanisms and novel therapeutic strategies"],"prefix":"10.1515","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9836-7750","authenticated-orcid":false,"given":"Malchi","family":"Suresh","sequence":"first","affiliation":[{"name":"Department of Research, Meenakshi Academy of Higher Education and Research , (MAHER\u00a0\u2013\u00a0Deemed to be University) , Chennai , Tamil Nadu , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakthivel Manju","family":"Bargavi","sequence":"additional","affiliation":[{"name":"Department of Nutrition and Dietetics, Faculty of Humanities and Science, Meenakshi Academy of Higher Education and Research , (MAHER\u00a0\u2013\u00a0Deemed to be University) , Chennai , Tamil Nadu , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kodiganti Naresh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Research, Meenakshi Academy of Higher Education and Research , (MAHER\u00a0\u2013\u00a0Deemed to be University) , Chennai , Tamil Nadu , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namani","family":"Sreevani","sequence":"additional","affiliation":[{"name":"Department of Research and Development , Saveetha Institute of Medical and Technical Sciences, Saveetha University , Chennai , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devarajan","family":"Nalini","sequence":"additional","affiliation":[{"name":"Department of Research, Meenakshi Academy of Higher Education and Research , (MAHER\u00a0\u2013\u00a0Deemed to be University) , Chennai , Tamil Nadu , India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_001","doi-asserted-by":"crossref","unstructured":"Chen, X, Liu, M, Meng, F, Sun, B, Jin, X, Jia, C. The long noncoding RNA HIF1A\u2010AS2 facilitates cisplatin resistance in bladder cancer. J\u00a0Cell Biochem 2019;120:243\u201352. https:\/\/doi.org\/10.1002\/jcb.27327.","DOI":"10.1002\/jcb.27327"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_002","doi-asserted-by":"crossref","unstructured":"Hockel, M, Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J\u00a0Natl Cancer Inst 2001;93:266\u201376. https:\/\/doi.org\/10.1093\/jnci\/93.4.266.","DOI":"10.1093\/jnci\/93.4.266"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_003","doi-asserted-by":"crossref","unstructured":"Harris, AL. Hypoxia\u00a0\u2013\u00a0A key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38\u201347. https:\/\/doi.org\/10.1038\/nrc704.","DOI":"10.1038\/nrc704"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_004","doi-asserted-by":"crossref","unstructured":"Semenza, GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012;33:207\u201314. https:\/\/doi.org\/10.1016\/j.tips.2012.01.005.","DOI":"10.1016\/j.tips.2012.01.005"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_005","doi-asserted-by":"crossref","unstructured":"Wouters, BG, Koritzinsky, M, Chiu, RK, Theys, J, Buijsen, J, Lambin, P, editors. Modulation of cell death in the tumor microenvironment. Maastricht: WB Saunders; 2003:31\u201341 pp.","DOI":"10.1053\/srao.2003.50004"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_006","doi-asserted-by":"crossref","unstructured":"Semenza, GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721\u201332. https:\/\/doi.org\/10.1038\/nrc1187.","DOI":"10.1038\/nrc1187"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_007","doi-asserted-by":"crossref","unstructured":"Wang, GL, Jiang, B-h, Rue, EA, Semenza, GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci 1995;92:5510\u20134. https:\/\/doi.org\/10.1073\/pnas.92.12.5510.","DOI":"10.1073\/pnas.92.12.5510"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_008","doi-asserted-by":"crossref","unstructured":"Wilson, WR, Hay, MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011;11:393\u2013410. https:\/\/doi.org\/10.1038\/nrc3064.","DOI":"10.1038\/nrc3064"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_009","doi-asserted-by":"crossref","unstructured":"Song, X, Liu, X, Chi, W, Liu, Y, Wei, L, Wang, X, et al.. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1\u03b1 gene. Cancer Chemother Pharmacol 2006;58:776\u201384. https:\/\/doi.org\/10.1007\/s00280-006-0224-7.","DOI":"10.1007\/s00280-006-0224-7"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_010","doi-asserted-by":"crossref","unstructured":"Feng, X, Liu, N, Deng, S, Zhang, D, Wang, K, Lu, M. miR-199a modulates cisplatin resistance in ovarian cancer by targeting Hif1\u03b1. OncoTargets Ther 2017:5899\u2013906. https:\/\/doi.org\/10.2147\/ott.s145833.","DOI":"10.2147\/OTT.S145833"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_011","doi-asserted-by":"crossref","unstructured":"Lau, CK, Yang, ZF, Ho, DW, Ng, MN, Yeoh, GCT, Poon, RTP, et al.. An Akt\/Hypoxia-inducible factor-1\u03b1\/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin Cancer Res 2009;15:3462\u201371. https:\/\/doi.org\/10.1158\/1078-0432.ccr-08-2127.","DOI":"10.1158\/1078-0432.CCR-08-2127"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_012","doi-asserted-by":"crossref","unstructured":"Zhao, L, Li, W, Zhou, Y, Zhang, Y, Huang, S, Xu, X, et al.. The overexpression and nuclear translocation of Trx-1 during hypoxia confers on HepG2 cells resistance to DDP, and GL-V9 reverses the resistance by suppressing the Trx-1\/Ref-1 axis. Free Radic Biol Med 2015;82:29\u201341. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2015.01.014.","DOI":"10.1016\/j.freeradbiomed.2015.01.014"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_013","doi-asserted-by":"crossref","unstructured":"Nijwening, JH, Kuiken, HJ, Beijersbergen, RL. Screening for modulators of cisplatin sensitivity: unbiased screens reveal common themes. Cell Cycle 2011;10:380\u20136. https:\/\/doi.org\/10.4161\/cc.10.3.14642.","DOI":"10.4161\/cc.10.3.14642"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_014","unstructured":"Kondo, A, Safaei, R, Mishima, M, Niedner, H, Lin, X, Howell, SB. Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Res 2001;61:7603\u20137."},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_015","doi-asserted-by":"crossref","unstructured":"Wu, Y-C, Ling, T-Y, Lu, S-H, Kuo, H-C, Ho, H-N, Yeh, S-D, et al.. Chemotherapeutic sensitivity of testicular germ cell tumors under hypoxic conditions is negatively regulated by SENP1-controlled sumoylation of OCT4. Cancer Res 2012;72:4963\u201373. https:\/\/doi.org\/10.1158\/0008-5472.can-12-0673.","DOI":"10.1158\/0008-5472.CAN-12-0673"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_016","doi-asserted-by":"crossref","unstructured":"Van Niel, G, d\u2019Angelo, G, Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol 2018;19:213\u201328. https:\/\/doi.org\/10.1038\/nrm.2017.125.","DOI":"10.1038\/nrm.2017.125"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_017","doi-asserted-by":"crossref","unstructured":"Dorayappan, KDP, Wanner, R, Wallbillich, JJ, Saini, U, Zingarelli, R, Suarez, AA, et al.. Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3\/Rab proteins. Oncogene 2018;37:3806\u201321. https:\/\/doi.org\/10.1038\/s41388-018-0189-0.","DOI":"10.1038\/s41388-018-0189-0"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_018","doi-asserted-by":"crossref","unstructured":"Patra, SK, Sahoo, RK, Biswal, S, Panda, SS, Biswal, BK. Enigmatic exosomal connection in lung cancer drug resistance. Mol Ther Nucleic Acids 2024;35:101896.","DOI":"10.1016\/j.omtn.2024.102177"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_019","doi-asserted-by":"crossref","unstructured":"Kim, J-w, Tchernyshyov, I, Semenza, GL, Dang, CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3:177\u201385. https:\/\/doi.org\/10.1016\/j.cmet.2006.02.002.","DOI":"10.1016\/j.cmet.2006.02.002"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_020","doi-asserted-by":"crossref","unstructured":"Shimanishi, M, Ogi, K, Sogabe, Y, Kaneko, T, Dehari, H, Miyazaki, A, et al.. Silencing of GLUT\u20101 inhibits sensitization of oral cancer cells to cisplatin during hypoxia. J\u00a0Oral Pathol Med 2013;42:382\u20138. https:\/\/doi.org\/10.1111\/jop.12028.","DOI":"10.1111\/jop.12028"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_021","doi-asserted-by":"crossref","unstructured":"Gu, J, Li, Y, Zeng, J, Wang, B, Ji, K, Tang, Y, et al.. Knockdown of HIF-1\u03b1 by siRNA-expressing plasmid delivered by attenuated Salmonella enhances the antitumor effects of cisplatin on prostate cancer. Sci Rep 2017;7:7546. https:\/\/doi.org\/10.1038\/s41598-017-07973-4.","DOI":"10.1038\/s41598-017-07973-4"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_022","doi-asserted-by":"crossref","unstructured":"Han, Y, Kim, B, Cho, U, Park, IS, Kim, SI, Dhanasekaran, DN, et al.. Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells. Oncogene 2019;38:7089\u2013105. https:\/\/doi.org\/10.1038\/s41388-019-0949-5.","DOI":"10.1038\/s41388-019-0949-5"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_023","doi-asserted-by":"crossref","unstructured":"Syu, J-P, Chi, J-T, Kung, H-N. Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia. Oncotarget 2016;7:14659. https:\/\/doi.org\/10.18632\/oncotarget.7406.","DOI":"10.18632\/oncotarget.7406"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_024","doi-asserted-by":"crossref","unstructured":"Shrivastava, S, Shrivastava, P. Working together to reduce the incidence of cancers in low-and middle-income nations: World health organization. Clin Cancer Investig J 2020;9:61\u20132. https:\/\/doi.org\/10.4103\/ccij.ccij_17_20.","DOI":"10.4103\/ccij.ccij_17_20"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_025","doi-asserted-by":"crossref","unstructured":"Liu, DSH, Read, M, Cullinane, C, Azar, WJ, Fennell, CM, Montgomery, KG, et al.. APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma. Gut 2015;64:1506\u201316. https:\/\/doi.org\/10.1136\/gutjnl-2015-309770.","DOI":"10.1136\/gutjnl-2015-309770"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_026","doi-asserted-by":"crossref","unstructured":"Hirano, T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol 2021;33:127\u201348. https:\/\/doi.org\/10.1093\/intimm\/dxaa078.","DOI":"10.1093\/intimm\/dxaa078"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_027","doi-asserted-by":"crossref","unstructured":"Wu, H-M, Jiang, Z-F, Ding, P-S, Shao, L-J, Liu, R-Y. Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells. Sci Rep 2015;5:12291. https:\/\/doi.org\/10.1038\/srep12291.","DOI":"10.1038\/srep12291"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_028","doi-asserted-by":"crossref","unstructured":"Thigpen, T, McAlpine, J, DiSaia, P, Fujiwara, K, Hoskins, W, Kristensen, G, et al.. First-line therapy in ovarian cancer trials. Int J Gynecol Cancer 2011;21:756\u201362. https:\/\/doi.org\/10.1097\/igc.0b013e31821ce75d.","DOI":"10.1097\/IGC.0b013e31821ce75d"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_029","doi-asserted-by":"crossref","unstructured":"Tak, E, Lee, S, Lee, J, Rashid, MA, Kim, YW, Park, J-H, et al.. Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells. J\u00a0Hepatol 2011;54:328\u201339. https:\/\/doi.org\/10.1016\/j.jhep.2010.06.045.","DOI":"10.1016\/j.jhep.2010.06.045"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_030","doi-asserted-by":"crossref","unstructured":"Choi, KJ, Piao, YJ, Lim, MJ, Kim, JH, Ha, J, Choe, W, et al.. Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia-and cisplatin-induced cell death. Cancer Res 2007;67:3654\u201362. https:\/\/doi.org\/10.1158\/0008-5472.can-06-1759.","DOI":"10.1158\/0008-5472.CAN-06-1759"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_031","doi-asserted-by":"crossref","unstructured":"Su, Y, Yang, W, Jiang, N, Shi, J, Chen, L, Zhong, G, et al.. Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin resistance. Int J Biol Sci 2019;15:441. https:\/\/doi.org\/10.7150\/ijbs.26826.","DOI":"10.7150\/ijbs.26826"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_032","doi-asserted-by":"crossref","unstructured":"Fischer, C, Leithner, K, Wohlkoenig, C, Quehenberger, F, Bertsch, A, Olschewski, A, et al.. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1\u03b1 destabilization. Mol Cancer 2015;14:1\u201316. https:\/\/doi.org\/10.1186\/1476-4598-14-4.","DOI":"10.1186\/1476-4598-14-4"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_033","doi-asserted-by":"crossref","unstructured":"Kim, Y, Jang, M, Lim, S, Won, H, Yoon, KS, Park, JH, et al.. Role of cyclophilin B in tumorigenesis and cisplatin resistance in hepatocellular carcinoma in humans. Hepatology 2011;54:1661\u201378. https:\/\/doi.org\/10.1002\/hep.24539.","DOI":"10.1002\/hep.24539"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_034","doi-asserted-by":"crossref","unstructured":"Yasuda, H, Yamaya, M, Nakayama, K, Sasaki, T, Ebihara, S, Kanda, A, et al.. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB\/IV non\u2013small-cell lung cancer. J\u00a0Clin Oncol 2006;24:688\u201394. https:\/\/doi.org\/10.1200\/jco.2005.04.0436.","DOI":"10.1200\/JCO.2005.04.0436"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_035","doi-asserted-by":"crossref","unstructured":"Pastorek, J, Pastorekova, S, editors. Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. Amsterdam: Elsevier, Academic Press; 2015.","DOI":"10.1016\/j.semcancer.2014.08.002"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_036","doi-asserted-by":"crossref","unstructured":"Sinha, S, Pal, K, Elkhanany, A, Dutta, S, Cao, Y, Mondal, G, et al.. Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in\u00a0vivo. Int J Cancer 2013;132:1201\u201312. https:\/\/doi.org\/10.1002\/ijc.27724.","DOI":"10.1002\/ijc.27724"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_037","doi-asserted-by":"crossref","unstructured":"Hussain, I, Waheed, S, Ahmad, KA, Pirog, JE, Syed, V. Scutellaria baicalensis targets the hypoxia\u2010inducible factor\u20101\u03b1 and enhances cisplatin efficacy in ovarian cancer. J\u00a0Cell Biochem 2018;119:7515\u201324. https:\/\/doi.org\/10.1002\/jcb.27063.","DOI":"10.1002\/jcb.27063"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_038","doi-asserted-by":"crossref","unstructured":"Huang, X-z, Wang, J, Huang, C, Chen, Y-y, Shi, G-y, Hu, Q-s, et al.. Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. Cancer Biol Ther 2008;7:468\u201375. https:\/\/doi.org\/10.4161\/cbt.7.3.5457.","DOI":"10.4161\/cbt.7.3.5457"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_039","doi-asserted-by":"crossref","unstructured":"Alagoz, T, Buller, RE, Anderson, B, Terrell, KL, Squatrito, RC, Niemann, TH, et al.. Evaluation of hyperbaric oxygen as a chemosensitizer in the treatment of epithelial ovarian cancer in xenografts in mice. Cancer 1995;75:2313\u201322. https:\/\/doi.org\/10.1002\/1097-0142(19950501)75:9<2313::aid-cncr2820750921>3.0.co;2-6.","DOI":"10.1002\/1097-0142(19950501)75:9<2313::AID-CNCR2820750921>3.0.CO;2-6"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_040","doi-asserted-by":"crossref","unstructured":"Peng, H-S, Liao, M-B, Zhang, M-Y, Xie, Y, Xu, L, Zhang, Y-J, et al.. Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells. PLoS One 2014;9:e100814. https:\/\/doi.org\/10.1371\/journal.pone.0100814.","DOI":"10.1371\/journal.pone.0100814"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_041","doi-asserted-by":"crossref","unstructured":"Song, D, Beringhs, AOR, Zhuang, Z, Joshi, G, Tran, TH, Claffey, KP, et al.. Overcoming hypoxia-induced chemoresistance to cisplatin through tumor oxygenation monitored by optical imaging. Nanotheranostics 2019;3:223. https:\/\/doi.org\/10.7150\/ntno.35935.","DOI":"10.7150\/ntno.35935"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_042","doi-asserted-by":"crossref","unstructured":"Gao, X-l, Zhang, M, Tang, Y-l, Liang, X-h. Cancer cell dormancy: mechanisms and implications of cancer recurrence and metastasis. OncoTargets Ther 2017:5219\u201328. https:\/\/doi.org\/10.2147\/ott.s140854.","DOI":"10.2147\/OTT.S140854"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_043","doi-asserted-by":"crossref","unstructured":"Yao, K, Gietema, JA, Shida, S, Selvakumaran, M, Fonrose, X, Haas, NB, et al.. In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in\u00a0vivo. Br J Cancer 2005;93:1356\u201363. https:\/\/doi.org\/10.1038\/sj.bjc.6602864.","DOI":"10.1038\/sj.bjc.6602864"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_044","doi-asserted-by":"crossref","unstructured":"Pradhan, S, Mahajan, D, Kaur, P, Pandey, N, Sharma, C, Srivastava, T. Scriptaid overcomes hypoxia induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells. Oncotarget 2016;7:71841\u201355. https:\/\/doi.org\/10.18632\/oncotarget.12378.","DOI":"10.18632\/oncotarget.12378"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_045","doi-asserted-by":"crossref","unstructured":"Berghauser, PLM, Kleijn, A, Kloezeman, JJ, van den Bossche, W, Kaufmann, JK, de Vrij, J, et al.. The HDAC inhibitors scriptaid and LBH589 combined with the oncolytic virus Delta24-RGD exert enhanced anti-tumor efficacy in patient-derived glioblastoma cells. PLoS One 2015;10:e0127058. https:\/\/doi.org\/10.1371\/journal.pone.0127058.","DOI":"10.1371\/journal.pone.0127058"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_046","doi-asserted-by":"crossref","unstructured":"Janyst, K, Janyst, M, Siernicka, M, Lasek, W. Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells. Oncol Rep 2018;39:1999\u20132005. https:\/\/doi.org\/10.3892\/or.2018.6248.","DOI":"10.3892\/or.2018.6248"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_047","doi-asserted-by":"crossref","unstructured":"Van Veggel, M, Westerman, E, Hamberg, P. Clinical pharmacokinetics and pharmacodynamics of panobinostat. Clin Pharmacokinet 2018;57:21\u20139. https:\/\/doi.org\/10.1007\/s40262-017-0565-x.","DOI":"10.1007\/s40262-017-0565-x"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_048","doi-asserted-by":"crossref","unstructured":"Wahaib, K, Beggs, AE, Campbell, H, Kodali, L, Ford, PD. Panobinostat: a histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma. Am J Health Syst Pharm 2016;73:441\u201350. https:\/\/doi.org\/10.2146\/ajhp150487.","DOI":"10.2146\/ajhp150487"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_049","doi-asserted-by":"crossref","unstructured":"Foretz, M, Guigas, B, Viollet, B. Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol 2023;19:460\u201376. https:\/\/doi.org\/10.1038\/s41574-023-00833-4.","DOI":"10.1038\/s41574-023-00833-4"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_050","doi-asserted-by":"crossref","unstructured":"Mohammed, I, Hollenberg, MD, Ding, H, Triggle, CR. A critical review of the evidence that metformin is a putative anti-aging drug that enhances healthspan and extends lifespan. Front Endocrinol 2021;12:718942. https:\/\/doi.org\/10.3389\/fendo.2021.718942.","DOI":"10.3389\/fendo.2021.718942"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_051","doi-asserted-by":"crossref","unstructured":"Reymen, BJT, van Gisbergen, MW, Even, AJG, Zegers, CM, Das, M, Vegt, E, et al.. Nitroglycerin as a radiosensitizer in non-small cell lung cancer: results of a prospective imaging-based phase II trial. Clin Transl Radiat Oncol 2019;21:49\u201355. https:\/\/doi.org\/10.1016\/j.ctro.2019.12.002.","DOI":"10.1016\/j.ctro.2019.12.002"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_052","doi-asserted-by":"crossref","unstructured":"Pastorek, M, Simko, V, Takacova, M, Barathova, M, Bartosova, M, Hunakova, L, et al.. Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy. Int J Oncol 2015;47:51\u201360. https:\/\/doi.org\/10.3892\/ijo.2015.2987.","DOI":"10.3892\/ijo.2015.2987"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_053","doi-asserted-by":"crossref","unstructured":"Kandala, PK, Srivastava, SK. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3). BMC Med 2012;10:9. https:\/\/doi.org\/10.1186\/1741-7015-10-9.","DOI":"10.1186\/1741-7015-10-9"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_054","doi-asserted-by":"crossref","unstructured":"Reed, GA, Sunega, JM, Sullivan, DK, Gray, JC, Mayo, MS, Crowell, JA, et al.. Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3\u2019-diindolylmethane in healthy subjects. Cancer Epidemiol Biomarkers Prev 2008;17:2619\u201324. https:\/\/doi.org\/10.1158\/1055-9965.epi-08-0520. do.","DOI":"10.1158\/1055-9965.EPI-08-0520"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_055","doi-asserted-by":"crossref","unstructured":"Zhou, X, Fu, L, Wang, P, Yang, L, Zhu, X, Li, CG. Drug-herb interactions between Scutellaria baicalensis and pharmaceutical drugs: insights from experimental studies, mechanistic actions to clinical applications. Biomed Pharmacother 2021;138:111445. https:\/\/doi.org\/10.1016\/j.biopha.2021.111445.","DOI":"10.1016\/j.biopha.2021.111445"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_056","doi-asserted-by":"crossref","unstructured":"Zieniuk, B, U\u011fur, \u015e. The therapeutic potential of Baicalin and Baicalein in breast cancer: a systematic review of mechanisms and efficacy. Curr Issues Mol Biol 2025;47:181. https:\/\/doi.org\/10.3390\/cimb47030181.","DOI":"10.3390\/cimb47030181"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_057","doi-asserted-by":"crossref","unstructured":"Akkol, EK, Tatl\u0131, II, Karatoprak, G\u015e, A\u011far, OT, Y\u00fccel, \u00c7, Sobarzo-S\u00e1nchez, E, et al.. Is emodin with anticancer effects completely innocent? Two sides of the coin. Cancers 2021;13:2733. https:\/\/doi.org\/10.3390\/cancers13112733.","DOI":"10.3390\/cancers13112733"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_058","doi-asserted-by":"crossref","unstructured":"Li, X, Wang, H, Wang, J, Chen, Y, Yin, X, Shi, G, et al.. Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation. BMC Cancer 2016;16:578. https:\/\/doi.org\/10.1186\/s12885-016-2640-3.","DOI":"10.1186\/s12885-016-2640-3"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_059","doi-asserted-by":"crossref","unstructured":"Li, X, Wu, Y, Zhang, R, Bai, W, Ye, T, Wang, S. Oxygen-based nanocarriers to modulate tumor hypoxia for ameliorated anti-tumor therapy: fabrications, properties, and future directions. Front Mol Biosci 2021;8:683519. https:\/\/doi.org\/10.3389\/fmolb.2021.683519.","DOI":"10.3389\/fmolb.2021.683519"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_060","doi-asserted-by":"crossref","unstructured":"He, C, Zhang, X, Yan, R, Zhao, P, Chen, Y, Li, M, et al.. Enhancement of cisplatin efficacy by lipid-CaO2 nanocarrier-mediated comprehensive modulation of the tumor microenvironment. Biomater Sci 2019;7:4260\u201372. https:\/\/doi.org\/10.1039\/c9bm00797k.","DOI":"10.1039\/C9BM00797K"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_061","doi-asserted-by":"crossref","unstructured":"Fan, D, Cao, Y, Cao, M, Wang, Y, Cao, Y, Gong, T. Nanomedicine in cancer therapy. Signal Transduct Targeted Ther 2023;8:293. https:\/\/doi.org\/10.1038\/s41392-023-01536-y.","DOI":"10.1038\/s41392-023-01536-y"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_062","doi-asserted-by":"crossref","unstructured":"Fujita, H, Hirose, K, Sato, M, Fujioka, I, Fujita, T, Aoki, M, et al.. Metformin attenuates hypoxia-induced resistance to cisplatin in the HepG2 cell line. Oncol Lett 2019;17:2431\u201340. https:\/\/doi.org\/10.3892\/ol.2018.9869.","DOI":"10.3892\/ol.2018.9869"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_063","doi-asserted-by":"crossref","unstructured":"Sailo, BL, Liu, L, Chauhan, S, Girisa, S, Hegde, M, Liang, L, et al.. Harnessing sulforaphane potential as a chemosensitizing agent: a comprehensive review. Cancers (Basel) 2024;16:244. https:\/\/doi.org\/10.3390\/cancers16020244.","DOI":"10.3390\/cancers16020244"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_064","doi-asserted-by":"crossref","unstructured":"Yuan, JM, Kensler, TW, Dacic, S, Hartman, DJ, Wang, R, Balogh, PA, et al.. Randomized phase II clinical trial of sulforaphane in former smokers at high risk for lung cancer. Cancer Prev Res 2025;18:335\u201345. https:\/\/doi.org\/10.1158\/1940-6207.capr-24-0386.","DOI":"10.1158\/1940-6207.CAPR-24-0386"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_065","doi-asserted-by":"crossref","unstructured":"Reyes-Hern\u00e1ndez, OD, Figueroa-Gonz\u00e1lez, G, Quintas-Granados, LI, Guti\u00e9rrez-Ru\u00edz, SC, Hern\u00e1ndez-Parra, H, Romero-Montero, A, et al.. 3,3\u2019-Diindolylmethane and indole-3-carbinol: potential therapeutic molecules for cancer chemoprevention and treatment via regulating cellular signaling pathways. Cancer Cell Int 2023;23:180. https:\/\/doi.org\/10.1186\/s12935-023-03031-4.","DOI":"10.1186\/s12935-023-03031-4"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_066","doi-asserted-by":"crossref","unstructured":"Sougiannis, AT, Enos, RT, VanderVeen, BN, Velazquez, KT, Kelly, B, McDonald, S, et al.. Safety of natural anthraquinone emodin: an assessment in mice. BMC Pharmacol Toxicol 2021;22:9. https:\/\/doi.org\/10.1186\/s40360-021-00474-1.","DOI":"10.1186\/s40360-021-00474-1"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_067","doi-asserted-by":"crossref","unstructured":"Qi, X, Wong, BL, Lau, SH, Tak-Pan Ng, K, Kwok, SY, Kin-Wai Sun, C, et al.. A hemoglobin-based oxygen carrier sensitized Cisplatin based chemotherapy in hepatocellular carcinoma. Oncotarget 2017;8:85311\u201325. https:\/\/doi.org\/10.18632\/oncotarget.19672.","DOI":"10.18632\/oncotarget.19672"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_068","doi-asserted-by":"crossref","unstructured":"Kuang, L, Zhu, Y, Wu, Y, Tian, K, Peng, X, Xue, M, et al.. A novel cross-linked hemoglobin-based oxygen carrier, YQ23, extended the golden hour for uncontrolled hemorrhagic shock in rats and miniature pigs. Front Pharmacol 2021;12:652716. https:\/\/doi.org\/10.3389\/fphar.2021.652716.","DOI":"10.3389\/fphar.2021.652716"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_069","doi-asserted-by":"crossref","unstructured":"Wang Q, Yang J, Sun M, Dang L, Shestakova L, Ostrovsky Y, et al.. Advanced oxygen therapeutics for treatments of acute hemorrhagic shock and organ preservation. Smart Mater Med 2025;6:139\u201351.","DOI":"10.1016\/j.smaim.2025.04.001"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_070","doi-asserted-by":"crossref","unstructured":"Gan, Y, Xie, W, Wang, M, Wang, P, Li, Q, Cheng, J, et al.. Cancer cell membrane-camouflaged CuPt nanoalloy boosts chemotherapy of cisplatin prodrug to enhance anticancer effect and reverse cisplatin resistance of tumor. Mater Today Bio 2024;24:100941. https:\/\/doi.org\/10.1016\/j.mtbio.2023.100941.","DOI":"10.1016\/j.mtbio.2023.100941"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_071","doi-asserted-by":"crossref","unstructured":"Guo, Q, Wang, S, Xu, R, Tang, Y, Xia, X. Cancer cell membrane-coated nanoparticles: a promising anti-tumor bionic platform. RSC Adv 2024;14:10608\u201337. https:\/\/doi.org\/10.1039\/d4ra01026d.","DOI":"10.1039\/D4RA01026D"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_072","doi-asserted-by":"crossref","unstructured":"Bui, BP, Nguyen, PL, Lee, K, Cho, J. Hypoxia-inducible Factor-1: a novel therapeutic target for the management of cancer, drug resistance, and cancer-related pain. Cancers (Basel) 2022;14:6054. https:\/\/doi.org\/10.3390\/cancers14246054.","DOI":"10.3390\/cancers14246054"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_073","doi-asserted-by":"crossref","unstructured":"Kunachowicz, D, Tomecka, P, S\u0119dzik, M, Kalinin, J, Ku\u017anicki, J, Rembia\u0142kowska, N. Influence of hypoxia on tumor heterogeneity, DNA repair, and cancer therapy: from molecular insights to therapeutic strategies. Cells 2025;14:1057. https:\/\/doi.org\/10.3390\/cells14141057.","DOI":"10.3390\/cells14141057"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_074","doi-asserted-by":"crossref","unstructured":"Zhang, X, He, C, Yan, R, Chen, Y, Zhao, P, Li, M, et al.. HIF-1 dependent reversal of cisplatin resistance via anti-oxidative nano selenium for effective cancer therapy. Chem Eng J 2020;15:380. 122540.","DOI":"10.1016\/j.cej.2019.122540"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_075","doi-asserted-by":"crossref","unstructured":"Yan, Y, He, M, Zhao, L, Wu, H, Zhao, Y, Han, L, et al.. A novel HIF-2\u03b1 targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI\/GPR78-UPRER axis. Cell Death Differ 2022;29:1769\u201389. https:\/\/doi.org\/10.1038\/s41418-022-00963-8.","DOI":"10.1038\/s41418-022-00963-8"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_076","doi-asserted-by":"crossref","unstructured":"Toledo, RA, Jimenez, C, Armaiz-Pena, G, Arenillas, C, Capdevila, J, Dahia, PLM. Hypoxia-inducible factor 2 alpha (HIF2\u03b1) inhibitors: targeting genetically driven tumor hypoxia. Endocr Rev 2023;44:312\u201322. https:\/\/doi.org\/10.1210\/endrev\/bnac025.","DOI":"10.1210\/endrev\/bnac025"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_077","doi-asserted-by":"crossref","unstructured":"McDonald, PC, Chafe, SC, Supuran, CT, Dedhar, S. Cancer therapeutic targeting of hypoxia induced carbonic anhydrase IX: from bench to bedside. Cancers (Basel) 2022;14:3297. https:\/\/doi.org\/10.3390\/cancers14143297.","DOI":"10.3390\/cancers14143297"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_078","unstructured":"Ledaki, I. Heterogeneity of tumour response to hypoxia: carbonic anhydrase IX induction defines a subpopulation of hypoxic cells with stem cell properties and drug resistance. In: Diss. UK: Oxford University; 2013."},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_079","doi-asserted-by":"crossref","unstructured":"Eustace, A, Mani, N, Span, PN, Irlam, JJ, Taylor, J, Betts, GN, et al.. A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. Clin Cancer Res 2013;19:4879\u201388. https:\/\/doi.org\/10.1158\/1078-0432.ccr-13-0542.","DOI":"10.1158\/1078-0432.CCR-13-0542"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_080","doi-asserted-by":"crossref","unstructured":"Carles, M, Fechter, T, Grosu, AL, S\u00f6rensen, A, Thomann, B, Stoian, RG, et al.. 18F-FMISO-PET hypoxia monitoring for head-and-neck cancer patients: radiomics analyses predict the outcome of chemo-radiotherapy. Cancers (Basel) 2021;13:3449. https:\/\/doi.org\/10.3390\/cancers13143449.","DOI":"10.3390\/cancers13143449"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_081","doi-asserted-by":"crossref","unstructured":"Yoon, J, Kang, SY, Lee, K-H, Cheon, GJ, Oh, D-Y. Targeting hypoxia using evofosfamide and companion hypoxia imaging of FMISO-PET in advanced biliary tract cancer. In: Cancer research and treatment. Korea: Korean Cancer Association; 2021:471\u20139 pp.","DOI":"10.4143\/crt.2020.577"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_082","doi-asserted-by":"crossref","unstructured":"Wang, D, Zhao, C, Xu, F, Zhang, A, Jin, M, Zhang, K, et al.. Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2. Theranostics 2021;11:2860\u201375. https:\/\/doi.org\/10.7150\/thno.51797.","DOI":"10.7150\/thno.51797"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_083","doi-asserted-by":"crossref","unstructured":"Sullivan, EJ, Kurtoglu, M, Brenneman, R, Liu, H, Lampidis, TJ. Targeting cisplatin-resistant human tumor cells with metabolic inhibitors. Cancer Chemother Pharmacol 2014;73:417\u201327. https:\/\/doi.org\/10.1007\/s00280-013-2366-8.","DOI":"10.1007\/s00280-013-2366-8"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_084","doi-asserted-by":"crossref","unstructured":"Bae, T, Hallis, SP, Kwak, MK. Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer. Exp Mol Med 2024;56:501\u201314. https:\/\/doi.org\/10.1038\/s12276-024-01180-8.","DOI":"10.1038\/s12276-024-01180-8"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_085","doi-asserted-by":"crossref","unstructured":"Synowiec, A, Brodaczewska, K, Wcis\u0142o, G, Majewska, A, Borkowska, A, Filipiak-Duliban, A, et al.. Hypoxia, but not normoxia, reduces effects of resveratrol on cisplatin treatment in A2780 ovarian cancer cells: a challenge for resveratrol use in anticancer adjuvant cisplatin therapy. Int J Mol Sci 2023;24:5715. https:\/\/doi.org\/10.3390\/ijms24065715.","DOI":"10.3390\/ijms24065715"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_086","doi-asserted-by":"crossref","unstructured":"Song, K, Li, M, Xu, XJ, Xuan, L, Huang, GN, Song, XL, et al.. HIF-1\u03b1 and GLUT1 gene expression is associated with chemoresistance of acute myeloid leukemia. Asian Pac J Cancer Prev APJCP 2014;15:1823\u20139. https:\/\/doi.org\/10.7314\/apjcp.2014.15.4.1823.","DOI":"10.7314\/APJCP.2014.15.4.1823"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_087","doi-asserted-by":"crossref","unstructured":"Jiang, T, Zhou, ML, Fan, J. Inhibition of GLUT-1 expression and the PI3K\/Akt pathway to enhance the chemosensitivity of laryngeal carcinoma cells in\u00a0vitro. OncoTargets Ther 2018;11:7865\u201372. https:\/\/doi.org\/10.2147\/ott.s176818.","DOI":"10.2147\/OTT.S176818"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_088","doi-asserted-by":"crossref","unstructured":"Li, DW, Dong, P, Wang, F, Chen, XW, Xu, CZ, Zhou, L. Hypoxia induced multidrug resistance of laryngeal cancer cells via hypoxia-inducible factor-1\u03b1. Asian Pac J Cancer Prev APJCP 2013;14:4853\u20138. https:\/\/doi.org\/10.7314\/apjcp.2013.14.8.4853.","DOI":"10.7314\/APJCP.2013.14.8.4853"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_089","doi-asserted-by":"crossref","unstructured":"Dou, L, Lu, E, Tian, D, Li, F, Deng, L, Zhang, Y. Adrenomedullin induces cisplatin chemoresistance in ovarian cancer through reprogramming of glucose metabolism. J\u00a0Transl Int Med 2023;11:169\u201377. https:\/\/doi.org\/10.2478\/jtim-2023-0091.","DOI":"10.2478\/jtim-2023-0091"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_090","doi-asserted-by":"crossref","unstructured":"Li, PG, El Hassouni, B, Sciarrillo, R, Funel, N, Mantini, G, Zeeuw van der Laan, EA, et al.. Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds. Br J Cancer 2020;123:644\u201356. https:\/\/doi.org\/10.1038\/s41416-020-0912-9.","DOI":"10.1038\/s41416-020-0912-9"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_091","doi-asserted-by":"crossref","unstructured":"Mao, X, Nanzhang, Xiao, J, Wu, H, Ding, K. Hypoxia-induced autophagy enhances cisplatin resistance in human bladder cancer cells by targeting hypoxia-inducible Factor-1\u03b1. J\u00a0Immunol Res. 2021;2021:8887437, https:\/\/doi.org\/10.1155\/2021\/8887437.","DOI":"10.1155\/2021\/8887437"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_092","doi-asserted-by":"crossref","unstructured":"Lee, PWT, Koseki, LR, Haitani, T, Harada, H, Kobayashi, M. Hypoxia-inducible factor-dependent and independent mechanisms underlying chemoresistance of hypoxic cancer cells. Cancers (Basel)\u00a02024;16:1729. https:\/\/doi.org\/10.3390\/cancers16091729.","DOI":"10.3390\/cancers16091729"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_093","doi-asserted-by":"crossref","unstructured":"Chen, Z, Han, F, Du, Y, Shi, H, Zhou, W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Targeted Ther 2023;8:70. https:\/\/doi.org\/10.1038\/s41392-023-01332-8.","DOI":"10.1038\/s41392-023-01332-8"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_094","doi-asserted-by":"crossref","unstructured":"Chiari, G, Fiandaca, G, Delitala, ME. Hypoxia-resistance heterogeneity in tumours: the impact of geometrical characterization of environmental niches and evolutionary trade-offs. A mathematical approach. Math Model Nat Phenom 2023;18:18. https:\/\/doi.org\/10.1051\/mmnp\/2023023.","DOI":"10.1051\/mmnp\/2023023"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_095","doi-asserted-by":"crossref","unstructured":"Riedel, S, Hietschold, P, Kr\u00f6mmelbein, C, Kunschmann, T, Konieczny, R, Knolle, W, et al.. Design of biomimetic collagen matrices by reagent-free electron beam induced crosslinking: structure-Property relationships and cellular response. Mater Des 2019;168:107606. https:\/\/doi.org\/10.1016\/j.matdes.2019.107606.","DOI":"10.1016\/j.matdes.2019.107606"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_096","doi-asserted-by":"crossref","unstructured":"Jeon, JS, Bersini, S, Gilardi, M, Dubini, G, Charest, JL, Moretti, M, et al.. Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation. Proc Natl Acad Sci 2015;112:214\u20139. https:\/\/doi.org\/10.1073\/pnas.1417115112.","DOI":"10.1073\/pnas.1417115112"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_097","doi-asserted-by":"crossref","unstructured":"Konantz, M, Balci, TB, Hartwig, UF, Dellaire, G, Andr\u00e9, MC, Berman, JN, et al.. Zebrafish xenografts as a tool for in\u00a0vivo studies on human cancer. Ann N Y Acad Sci 2012;1266:124\u201337. https:\/\/doi.org\/10.1111\/j.1749-6632.2012.06575.x.","DOI":"10.1111\/j.1749-6632.2012.06575.x"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_098","doi-asserted-by":"crossref","unstructured":"Hidalgo, M, Amant, F, Biankin, AV, Budinsk\u00e1, E, Byrne, AT, Caldas, C, et al.. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 2014;4:998\u20131013. https:\/\/doi.org\/10.1158\/2159-8290.cd-14-0001.","DOI":"10.1158\/2159-8290.CD-14-0001"},{"key":"2026041004402361455_j_jbcpp-2025-0092_ref_099","doi-asserted-by":"crossref","unstructured":"Singh, R, Fazal, Z, Freemantle, SJ, Spinella, MJ. Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors. Cancer drug resistance 2019;2:580. https:\/\/doi.org\/10.20517\/cdr.2019.19.","DOI":"10.20517\/cdr.2019.19"}],"container-title":["Journal of Basic and Clinical Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2025-0092\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2025-0092\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:42:42Z","timestamp":1775796162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2025-0092\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":99,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,12,15]]},"published-print":{"date-parts":[[2026,4,8]]}},"alternative-id":["10.1515\/jbcpp-2025-0092"],"URL":"https:\/\/doi.org\/10.1515\/jbcpp-2025-0092","relation":{},"ISSN":["0792-6855","2191-0286"],"issn-type":[{"value":"0792-6855","type":"print"},{"value":"2191-0286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}